According to BioNTech CEO Ugur Sahin, the BNT162b1 produces antibody response at or above the levels seen in any convalescent serum; blood from people who have recovered – at relatively low doses.
The preliminary data come from a so-called phase 1/2 trial that aimed to show the vaccine is not toxic and triggers an immune system response to prepare the body to fight off the virus.
Of 45 people aged 18 to 55 who took part in the trial, most received two doses, 21 days apart, of the vaccine or a placebo.
A relatively high number of participants developed a fever after the second dose, according to a study uploaded on the pre-publication website medrxiv.org. But this is not unexpected and is not considered a stumbling block.
The vaccine relies on messenger RNA, a genetic code that slips into human cells to make them generate antibodies that are specifically tailored to the coronavirus.
Several companies have published results from the initial phases of clinical trials stating that their experimental vaccines cause an immune system response.
Several have moved to phase 2 or to phase 3 when they are injected into thousands of volunteers to evaluate their effectiveness, monitor side effects, and collect other information that will allow them to be used safely.
A vaccine created by the US biotech firm Moderna and one from Oxford University in collaboration with British-Swedish firm AstraZeneca is among those which are in the most advanced stages of development, along with several Chinese projects.